



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ³ : C12P 21/02	A1	(11) International Publication Number: WO 84/ 04336 (43) International Publication Date: 8 November 1984 (08.11.84)
(21) International Application Number: PCT/US84/00601 (22) International Filing Date: 18 April 1984 (18.04.84) (31) Priority Application Number: 487,753 (32) Priority Date: 22 April 1983 (22.04.83) (33) Priority Country: US (71) Applicant: AMGEN [US/US]; 1900 Oak Terrace Lane, Thousand Oaks, CA 91230 (US). (72) Inventor: BITTER, Grant, A. ; 3971 Calle Del Sol, Thousand Oaks, CA 91320 (US). (74) Agent: BORUN, Michael, F.; Marshall, O'Toole, Gers- tein, Murray & Bicknell, Two First National Plaza, Suite 2100, Chicago, IL 60603 (US).	(81) Designated State: JP. Published <i>With international search report.</i>	
(54) Title: SECRETION OF EXOGENOUS POLYPEPTIDES FROM YEAST (57) Abstract Recombinant methods and materials for use in securing production of exogenous (e.g., mammalian) polypeptides in yeast cells wherein hybrid precursor peptides susceptible to intracellular processing are formed and such processing results in secretion of desired polypeptides. In a presently preferred form, the invention provides transformation vectors with DNA sequences coding for yeast synthesis of hybrid precursor polypeptides comprising both an endogenous yeast polypeptide sequence (e.g., that of a precursor polypeptide associated with yeast-secreted mating factor α and an exogenous polypeptide sequence (e.g., human β -endorphin). Transformation of yeast cells with such DNA vectors results in secretion of desired exogenous polypeptide (e.g., substances displaying one or more of the biological properties of β -endorphin).		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	KN	Republic of Korea
AU	Australia	LI	Liechtenstein
BE	Belgium	LA	Laos
BG	Bulgaria	LU	Luxembourg
BR	Brazil	MC	Monaco
CF	Central African Republic	MG	Madagascar
CG	Congo	MR	Mauritania
CH	Switzerland	MW	Malawi
CM	Cameroon	NL	Netherlands
DE	Germany, Federal Republic of	NO	Norway
DK	Denmark	RO	Romania
FI	Finland	SD	Sudan
FR	France	SE	Sweden
GA	Gabon	SN	Senegal
GB	United Kingdom	SU	Soviet Union
HU	Hungary	TD	Chad
JP	Japan	TG	Togo
KP	Democratic People's Republic of Korea	US	United States of America

- 1 -

"SECRETION OF EXOGENOUS POLYPEPTIDES FROM YEAST"

BACKGROUND

5 The present invention relates generally to recombinant methods and materials for securing the microbial expression of exogenous genes coding for useful polypeptide products and for securing the recovery of such products from microbial cells. More particularly, 10 the present invention relates to the formation of exogenous polypeptides in yeast cells and to the secretion of desired polypeptide products so formed.

Numerous substantial advances have recently been made in the use of recombinant DNA methodologies 15 to secure the large-scale microbial production of eukaryotic (e.g., mammalian) gene products in prokaryotic and eukaryotic cells grown in culture. In essence, these advances have generally involved the introduction into bacterial, yeast, and higher eukaryote "host" cell 20 cultures of DNA sequences coding for polypeptides which wholly or partially duplicate the sequences of amino acids present in biologically active polypeptides ordinarily produced only in minute quantities by, e.g., specialized mammalian tissue cells. The hoped-for result 25 of such introductions is the stable genetic transformation of the host cells so that the polypeptides coded for by the exogenous genes will be produced in quantity by the protein manufacturing apparatus of the cells.

It has long been the goal of workers in this 30 field to devise methods and materials permitting not only the expression and stable accumulation of exogenous polypeptides of interest in host cells but also the secretory transport of intact polypeptide products from host cell cytoplasmic spaces into microbial periplasmic 35 spaces or, preferably, outside the cell into the surrounding medium.

With particular regard to the use of E.coli

- 2 -

bacterial cells as microbial hosts, it is known to attempt to secure expression of desired exogenous polypeptides as portions of so-called "fused" polypeptides including, e.g., endogenous enzymatic substances such as β -lactamase. Such enzymes normally migrate or are intracellularly processed toward E.coli periplasmic spaces and the fusion polypeptides including enzyme sequences are more or less readily isolated therefrom.

See, Talmadge, et al., PNAS (USA), 77, 3369-3373 (1980). Extracellular chemical or enzymatic cleavage is employed to yield the desired exogenous polypeptides in purified form. See, e.g., U.S. Letters Patent No. 4,366,246 to Riggs. At present, no analogous methods have been found to be readily applicable to microbial synthetic procedures involving lower eukaryotic host cells such as yeast cells (e.g., Saccharomyces cerevisiae).

A considerable body of knowledge has developed concerning the manner in which mammalian gene products, especially small regulatory polypeptides, are produced. See, generally, Herbert, et al., Cell, 30, 1-2 (1982). As one example, biosynthetic studies have revealed that certain regulatory peptides are derived from precursor proteins which are ten times the size or more than the biologically active peptides. This fact indicates that significant intracellular processing must take place prior to secretion of discrete active products by the cells. The peptides must be cut out of the precursor and are sometimes chemically modified to active forms prior to secretion. Cleavage from precursors and chemical modifications such as glycosylation, phosphorylation and secretion are generally believed to occur in a well-defined order as newly synthesized proteins pass through the membranes of the endoplasmic reticulum, Golgi complexes, and vesicles prior to secretion of biologically active fragments.



- 3 -

Studies of polypeptides secreted by yeast cells have indicated that at least somewhat analogous processing of precursor proteins occurs prior to secretion into yeast cell periplasmic spaces or outside the yeast cell wall. A very recent review article on this subject by Schekman, et al., appears at pages 361-393 in "The Molecular Biology of the Yeast *Saccharomyces*, Metabolism and Gene Expression", Cold Spring Harbor Press (1982). Briefly put, the review article and the references cited therein indicate that eleven endogenous yeast polypeptide products have been identified which are secreted either into the periplasmic space or into the cellular medium or, on occasion, into both. Among the yeast polypeptides ordinarily secreted into the cellular growth medium are two yeast pheromones, mating factor α and α_2 , pheromone peptidase, and "killer toxin". Among the yeast polypeptides ordinarily only transported to periplasmic spaces are invertase, L-asparaginase, and both the repressible and constitutive forms of acid phosphatase. Yeast products which have been isolated both from the periplasmic space and yeast cell culture medium include α -galactosidase, exo-1,3- β -glucanase, and endo-1,3- β -glucanase. The mechanisms which determine cell wall or extracellular location have not yet been elucidated.

The processing prior to secretion of certain of these polypeptides has been studied and it has generally been found that the products are initially expressed in cells in the form of precursor polypeptides having amino terminal regions including "signal" sequences (i.e., sequences of from 20-22 relatively hydrophobic amino acid residues believed to be functional in transport to the endoplasmic reticulum) and, in at least some instances, "pro" or "pre" sequences which are also ordinarily proteolytically cleaved from the portion of the precursor molecule to be secreted. See, Thill, et al., Mol. & Cell.Biol., 3, 570-579 (1983).



- 4 -

With the knowledge that yeast cells are capable of intracellular processing of endogenous precursor polypeptides in a manner analogous to the processing carried out in mammalian cell systems, studies were recently conducted concerning the potential for secretion of human interferons by yeast. See, Hitzeman, et al., Science, 219, 620-625 (1983). Briefly put, transformation vectors were constructed which included DNA sequences coding for synthesis of human interferons in the yeast Saccharomyces cerevisiae. It was reported that expression of interferon genes containing coding sequences for human "secretion signals" resulted in the secretion into the yeast cell culture medium of polypeptide fragments having interferon immunological activity. While the levels of interferon activity found in the medium were quite low and a significant percentage of the secreted material was incorrectly processed, the results of the studies were said to establish that lower eukaryotes such as yeast can rudimentarily utilize and intracellularly process human signal sequences in the manner of endogenous signal sequences.

Of particular interest to the background of the present invention is the developing body of information available concerning the synthesis and secretion of the yeast oligopeptide pheromone, or mating factor, commonly referred to as mating factor α ("MF α "). Mating in yeast appears to be facilitated by oligopeptide pheromones (mating factors) of two types, α and \underline{a} , that cause the arrest of cells of the opposite type in the G1 phase of the cell division cycle. Yeast cells of the α mating type produce MF α in tridecapeptide and dodecapeptide forms which differ on the basis of the presence or absence of a terminal tryptophan residue, while cells of the \underline{a} type produce MF \underline{a} in two alternative undecapeptide forms which differ in terms of the identity of the sixth amino acid residue.

- 6 -

```

      90      100      110      120
GAA ACG GCA CAA ATT CCG GCT GAA GCT GTC ATC GGT TAC TCA
Glu Thr Ala Gln Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser
      30
      130      140      150      160
5  GAT TTA GAA GGG GAT TTC GAT GTT GCT GTT TTG CCA TTT TCC
   Asp Leu Glu Gly Asp Phe Asp Val Ala Val Leu Pro Phe Ser
      50
      170      180      190      200      210
AAC AGC ACA AAT AAC GGG TTA TTG TTT ATA AAT ACT ACT ATT
Asn Ser Thr Asn Asn Gly Leu Leu Phe Ile Asn Thr Thr Ile
      60
10 GCC AGC ATT GCT GCT AAA GAA GAA GGG GTA TCT TTG GAT AAA
   Ala Ser Ile Ala Ala Lys Glu Glu Gly Val Ser Leu Asp Lys
      80
      220      230      240      250
      260      270      280      290
15 AGA GAG GCT GAA GCT TGG CAT TGG TTG CAA CTA AAA CCT GGC
   Arg Glu Ala Glu Ala Trp His Trp Leu Gln Leu Lys Pro Gly
      90
      300      310      320      HindIII
CAA CCA ATG TAC AAG AGA GAA GCC GAA GCT GAA GCT TGG CAT
Gln Pro Met Tyr Lys Arg Glu Ala Glu Ala Glu Ala Trp His
      102
      340      350      360      370
20 TGG CTG CAA CTA AAG CCT GGC CAA CCA ATG TAC AAA AGA GAA
   Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr Lys Arg Glu
      123
      380      HindIII      400      410      420
GCC GAC GCT GAA GCT TGG CAT TGG CTG CAA CTA AAG CCT GGC
Ala Asp Ala Glu Ala Trp His Trp Leu Gln Leu Lys Pro Gly
      132
      430      440      450      HindIII      460
CAA CCA ATG TAC AAA AGA GAA GCC GAC GCT GAA GCT TGG CAT
Gln Pro Met Tyr Lys Arg Glu Ala Asp Ala Glu Ala Trp His
      144
      470      480      490
30 TGG TTG CAG TTA AAA CCC GGC CAA CAA ATG TAC TAA
   Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr Stop
      165

```

As previously noted, the MFa gene described in Kurjan, et al., supra, is contained on a 1.7 kilobase EcoRI yeast genomic fragment. Production of the gene product is inactivated by cleavage with the endonuclease HindIII and it was noted that HindIII digestion yielded

- 8 -

While the work of Kurjan, et al. served to provide much valuable information and many valuable proposals concerning MF α synthesis and secretion in yeast, many questions significant to application of the information to systems other than those specifically involving MF α secretion remained unanswered. Among these was whether the above-noted 1.7kb EcoRI yeast genome fragment provides a self-contained sequence capable of directing synthesis of MF α (i.e., whether it included the entire endogenous promoter/regulator for precursor synthesis or, on the other hand, required the presence of other DNA sequences). Other unanswered questions included whether the presence of DNA "repeats" was required for MF α expression, whether the specific size of the MF α polypeptide is a critical factor in secretory processing events, and whether all potential copies of MF α in the precursor polypeptide are in fact secreted by yeast cells.

A recent publication by Julius, et al., Cell, 32, 839-852 (1983) serves to partially confirm the MF α precursor hypothesis of Kurjan, et al. in noting that mutant yeast strains defective in their capacity to produce certain membrane-bound, heat-stable dipeptidyl diaminopeptidase enzymes (coded for by the "stel3" gene) secrete incompletely processed forms of MF α having additional amino terminal residues duplicating "spacer" sequences described by Kurjan, et al. Restoration of the mutants' capacity to properly process MF α was demonstrated upon transformation of cells with plasmid-borne copies of the non-mutant form of the stel3 gene.

From the above description of the state of the art, it will be apparent that there continues to exist a need in the art for methods and materials for securing microbial expression of exogenous polypeptide products accompanied by some degree of intracellular secretory processing of products facilitating the isola-



- 9 -

tion of products in purified form. Despite varying degrees of knowledge concerning synthesis and processing of yeast-secreted polypeptides and despite some preliminary success in procedures involving yeast secretory processing of exogenous gene products in the form of exogenous precursor polypeptides, the art has been provided with no procedures which take joint advantage of yeast cell capacities both to synthesize exogenous gene products and to properly process endogenous precursor polypeptides in a manner permitting exogenous gene products to be secreted by transformed yeast cells.

BRIEF SUMMARY

According to one aspect of the invention, there are provided DNA sequences which code for yeast cell synthesis of novel hybrid polypeptides including, in one part, selected exogenous polypeptide amino acid sequence and, in another part, certain endogenous yeast polypeptide amino acid sequences. More particularly, the hybrid polypeptides coded for by DNA sequences of the present invention include, in their carboxyl terminal region, an exogenous polypeptide to be secreted by the yeast cells in which the hybrids are synthesized. Further, a portion of the amino terminal region of the hybrid polypeptides includes sequences of amino acids which duplicate "signal" or "pro" or "pre" sequences of amino terminal regions of endogenous polypeptide precursors of yeast-secreted polypeptides (which sequences are normally proteolytically cleaved from the endogenous precursors prior to polypeptide secretion into periplasmic spaces or into the yeast cell culture medium).

In another of its aspects, hybrid polypeptides coded for by DNA sequences of the invention may also include (normally proteolytically-cleaved) endogenous



- 10 -

yeast polypeptide sequences in their carboxyl terminal regions as well.

Endogenous yeast DNA sequences duplicated in hybrid polypeptides of the invention may be those extant in polypeptide precursors of various yeast-secreted polypeptides such as mating factor α , mating factor \underline{a} , killer toxin, invertase, repressible acid phosphatase, constitutive acid phosphatase, α -galactosidase, L-asparaginase, exo-1,3- β -glucanase, endo-1,3- β -glucanase and peromone peptidase. In presently preferred forms, DNA sequences of the invention code for hybrid polypeptides including endogenous polypeptides which duplicate one or more amino acid sequences found in polypeptide precursors of yeast-secreted MF α . The duplicated sequences may thus include part or all of the MF α precursor "signal" sequence; part or all of the MF α "pro" sequence; and/or part or all of one or more of the variant MF α "spacer" sequences as described by Kurjan, et al., supra.

Exogenous polypeptide constituents of hybrid polypeptides according to the invention may be of any desired length or amino acid sequence, with the proviso that it may be desirable to avoid sequences of amino acids which normally constitute sites for proteolytic cleavage of precursor polypeptides of yeast-secreted polypeptides. In an illustrative and presently preferred embodiment of the invention, an exemplary novel DNA sequence constructed codes for a hybrid polypeptide including, in its carboxyl terminal region, a human β -endorphin polypeptide.

According to another aspect of the invention, DNA transformation vectors are constructed which incorporate the above-noted novel DNA sequences. These vectors are employed to stably genetically transform yeast cells which are then grown in culture under conditions facilitating expression of desired hybrid polypeptides. The desired hybrids are, in turn, intracellularly



- 11 -

processed with the result that desired exogenous polypeptide products are secreted into yeast cell periplasmic spaces and/or outside the yeast cell wall into the yeast cell culture medium. In vectors of the present invention, expression of the novel DNA sequences may be regulated by any suitable promoter/regulator DNA sequence.

Illustrative examples of DNA transformation vectors of the invention include plasmids pYαE and pYαE on deposit under contract with the American Type Culture Collection, Rockville, Maryland, as ATCC Nos. 40068 and 40069, respectively. Both these plasmids include hybrid polypeptide coding regions under control of promoter/regulator sequences duplicating those associated with genomic expression of MFα by yeast cells. Plasmid pYαE (ATCC No. 40068) may be employed according to the present invention to transform a suitable Saccharomyces cerevisiae cell line (e.g., any α, leu2 strain such as GM3C-2) and the cultured growth of cells so transformed results in the accumulation, in the medium of cell growth, of polypeptide products possessing one or more of the biological activities (e.g., immunoreactivity) of human β-endorphin.

Other aspects and advantages of the invention will become apparent upon consideration of the following detailed description of preferred embodiments thereof.

DETAILED DESCRIPTION

The novel products and processes provided by the present invention are illustrated in the following examples which relate to manipulations involved in securing yeast cell synthesis and secretion of polypeptide substances having one or more of the biological activities of human β-endorphin. More specifically, Examples 1 through 7 relate to: (1) the isolation of an MFα structural gene as a DNA fragment from a yeast

- 12 -

genomic library and the partial sequencing of the cloned fragment; (2) the construction of a DNA sequence coding for human β -endorphin; (3) the ligation of the β -endorphin coding DNA sequence into the MFA structural gene; (4) the insertion of the resulting DNA sequence into a transformation vector; (5) the transformation of yeast cells with the resulting vector; (6) the isolation and characterization of polypeptide products secreted into the culture medium by transformed cells; and (7) the construction of an alternative transformation vector.

EXAMPLE 1

A Saccharomyces cerevisiae genome library in E.coli was screened with a synthetic oligonucleotide hybridization probe, and a plasmid with complementarity to the probe was cloned. From this cloned plasmid a 2.1kb EcoRI fragment with complementarity to the probe was subcloned in pBR322. The oligonucleotide probe used duplicates the sequence of bases later designated 474 through 498 of the sense strand DNA sequence set out in Figure 5 of Kurjan, et al., supra. Approximately 500 base pairs of the isolated fragment were initially sequenced by Maxam-Gilbert and dideoxy chain termination techniques and found to be essentially identical to the sequence of the protein coding region of an MFA structural gene set out by Kurjan, et al., supra. The 2.1kb fragment was digested with XbaI. The larger, 1.7kb digestion fragment obtained was ligated to a BamHI "linker" DNA sequence and inserted into an E.coli bacterial plasmid (pBRAH, i.e., pBR322 which had been modified to delete the HindIII site) cut with BamHI. The resulting plasmid, designated paFc, was amplified.

35



- 13 -

EXAMPLE 2

A DNA sequence coding for human [Leu⁵]
 5 β -endorphin polypeptide was synthesized and constructed
 according to the procedures of co-pending U.S. Patent
 Application Serial No. 375,493 filed May 6, 1982 by
 Stabinsky. The specific sequence constructed is set
 out in Table II below. Terminal base pair sequences
 10 outside the coding region are provided to facilitate
 insertion into the MFA structural gene as described,
infra.

TABLE II

15 HindIII
 Tyr Gly Gly Phe Leu Thr Ser Glu Lys Ser Gln Thr
 AGCT TAC GGT GGT TTC TTG ACC TCT GAA AAG TCT CAA ACT
 ATG CCA CCA AAG AAC TGG AGA CTT TTC AGA GTT TGA

 Pro Leu Val Thr Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala
 CCA TTG GTT ACT TTG TTC AAG AAC GCT ATC ATC AAG AAC GCT
 20 GGT AAC CAA TGA AAC AAG TTC TTG CGA TAG TAG TTC TTG CGA

 Tyr Lys Lys Gly Glu Ter Ter
 TAC AAG AAG GGT GAA TAA TAA GCTTG
 ATG TTC TTC CCA CTT ATT ATT CGAACCTAG

 HindII BamHI

25 The constructed sequence was cloned into the
 Rf M13mp9 which had been cut with HindIII and BamHI and
 the sequence was confirmed. The resulting Rf M13 DNA,
 designated M13/SEnd-9, was purified.

30

EXAMPLE 3

Plasmid p α Fc was digested with HindIII to
 delete three of the four MFA coding regions. As may
 be noted from the sequence of the protein-coding region
 35 of the MFA structural gene in Table I, after such endo-
 nuclease treatment there remained a HindIII sticky end



- 14 -

at the terminal portion of the first of the "spacer" amino acid sequences (Ala⁸⁹) and a HindIII sticky end just before the final MFa sequence (Trp¹⁵³).

5 M13/βEnd-9, containing the [Leu⁵] β-endorphin gene, was similarly digested with HindIII and the resulting 107 base pair fragment was purified and ligated into the HindIII cleaved pαFc to generate plasmid pαE. The DNA sequence thus generated is seen to code for synthesis
10 of a new hybrid polypeptide. In the new hybrid polypeptide, there is included, in the carboxyl terminal portion, an exogenous polypeptide, i.e., [Leu⁵] β-endorphin. In the new hybrid polypeptide, there are included sequences of amino acid residues duplicative of one or
15 more sequences which are extant in the amino terminal region of an endogenous polypeptide precursor of a selected yeast-secreted polypeptide (i.e., MFa) and which are normally proteolytically cleaved from the yeast-secreted polypeptide portion of the precursor prior to
20 secretion.

It may be here noted that in an alternative construction available according to the invention, a tandem repeating β-endorphin gene or other selected gene might be constructed and inserted into the HindIII
25 cleaved pαFc. In such a tandem repeating gene construction, the termination codons of the first β-endorphin coding sequence would be deleted and the first coding sequence would be separated from the second sequence by, e.g., a DNA sequence coding for part or all of one
30 of the alternative MFa "spacer" polypeptide forms. It would be preferred that alternative codons be employed in the region joining the spacer to the second β-endorphin sequence so that no HindIII restriction site would remain. Upon insertion as above, the novel DNA sequence
35 would code for a hybrid polypeptide which further included a normally proteolytically cleaved endogenous yeast sequence in its carboxyl terminal region, i.e.,



- 15 -

between two β -endorphin analog polypeptides. Similarly, multiple repeats of a selected exogenous gene may be incorporated separately by part or all of any of the variant spacers.

EXAMPLE 4

Plasmid p α E was digested with BamHI and the small fragment obtained was ligated into a high copy number yeast/E.coli shuttle vector pGT41 (cut with BamHI) to form plasmid pY α E (ATCC No. 40068) which was amplified in E.coli.

EXAMPLE 5

Plasmid pY α E was employed to transform a suitable α , Leu2⁻ strain of Saccharomyces cerevisiae (GM3C-2) wherein the Leu2⁺ phenotype allowed selection of transformants. Transformed cells were grown in culture at 30°C in 0.67 Yeast Nitrogen Base without amino acids (Difco), 2% glucose, 1% histidine and 1% tryptophan. Additionally, strain GM3C-2 transformed with a plasmid identical to pY α E, with the exception that the β -endorphin gene was in the opposite orientation, was cultured under identical conditions as a control.

EXAMPLE 6

Cultures from transformed and control cells were collected, centrifuged, and the supernatants tested for the presence of β -endorphin activity by means of a competitive radioimmunoassay for human β -endorphin [New England Nuclear Catalog No. NEK-003]. No activity at all was determined in the control media, while significant β -endorphin activity, on an order representing 200 micrograms of product per O.D. liter, was found in

- 16 -

the media from cultured growth of transformed cells.

5 EPLC analysis of the concentrated active media revealed three major RIA activity peaks. The most prominent peak, representing approximately one-third of the total β -endorphin activity, was isolated and amino acid sequencing revealed an essentially pure preparation of a polypeptide duplicating the sequence of the final 12 amino acid residues of human β -endorphin. Experimental procedures are under way to determine whether the 12 amino acid product is the result of intracellular proteolytic processing by the transformed cells or is an artifact generated by extracellular proteolytic cleavage occurring during handling of the culture medium. If the latter proves to be the case, protease inhibitors will be added to the medium in future isolative processing.

EXAMPLE 7

20 In order to determine whether secretory processing of yeast synthesized β -endorphin analog by transformed cells will be facilitated by reduction of the quantities of hybrid polypeptide produced, a single copy ("centromere") plasmid pYcaE (ATCC No. 40069) has been constructed with an inserted BamHI fragment from 25 paeE. Analysis of cell media of yeast transformed with this vector is presently under way.

In further experimental studies, the potential secretory rate limiting effects of available secretory processing enzymes will be determined. In one such procedure, yeast cells transformed with vectors of the invention will also be transformed to incorporate an 30 stel3 gene as described in Julius, et al., *supra*, so as to provide over-production of the heat stable dipeptidyl aminopeptidase believed to be involved in MFE secretory 35 processing.

- 17 -

While the foregoing illustrative examples relate to the construction of DNA sequences coding for "signal" and "pro" and "spacer" polypeptide sequences extant in the polypeptide precursor of MF α , it is expected that beneficial results may be secured when only one or two such sequences are coded for or when only a portion of such sequences (e.g., only the Lys-Arg portion of a spacer) are coded for. Similarly, while the yeast strain selected for secretory expression of exogenous polypeptide products was of the α phenotype, it is not necessarily the case that cells of the α phenotype would be unsuitable hosts since the essential secretory and processing activity may also be active in α cells. Finally, while expression of novel DNA sequences in the above illustrative examples was under control of an endogenous MF α promoter/regulator within the copy of the cloned genomic MF α -specifying DNA, it is expected that other yeast promoter DNA sequences may be suitably employed. Appropriate promoters may include yeast PGK and ADH-1 promoters or the G3PDH promoter of applicant's co-pending U.S. Patent Application Serial No. 412,707, filed August 3, 1982.

Although the above examples relate specifically to constructions involving DNA sequences associated with endogenous MF α secretion into yeast cell growth media, it will be understood that the successful results obtained strongly indicate the likelihood of success when DNA sequences associated with other yeast-secreted polypeptides (as noted above) are employed. In this regard, substantial benefits in polypeptide isolation are expected to attend intracellular secretory processing of exogenous polypeptides into yeast periplasmic spaces as well as into yeast growth media.

Numerous modifications and variations in the invention as represented by the above illustrative examples are expected to occur to those skilled in the art,



- 18 -

and consequently only such limitations as appear in the
appended claims should be placed upon the invention.

5

10

15

20

25

30

35



- 19 -

WHAT IS CLAIMED IS:

1. A DNA sequence coding for yeast cell synthesis of a hybrid polypeptide,
5 a portion of the carboxyl terminal region of said hybrid polypeptide comprising an exogenous polypeptide to be secreted by those yeast cells in which the hybrid polypeptide is synthesized,
10 a portion of the amino terminal region of said hybrid polypeptide comprising an endogenous yeast polypeptide characterized by including a sequence of amino acid residues duplicative of one or more sequences (1) extant in the amino terminal region of an endogenous polypeptide precursor of a selected yeast-secreted polypeptide, and (2) normally proteolytically cleaved from
15 the yeast-secreted polypeptide portion of the endogenous polypeptide precursor prior to secretion.
2. A DNA sequence according to claim 1 wherein
20 the endogenous yeast polypeptide comprising a portion of the amino terminal region of said hybrid polypeptide coded for includes a sequence of amino acid residues duplicative of one or more sequences extant in the amino terminal region of a polypeptide precursor of a yeast-
25 secreted polypeptide selected from the group consisting of:
mating factor α , mating factor \underline{a} , pheromone peptidase, killer toxin, invertase repressible acid phosphatase, constitutive acid phosphatase, α -galactosidase, L-asparaginase, exo-1,3- β -glucanase, and endo-1,3-
30 β -glucanase.
3. A DNA sequence according to claim 2 wherein
35 the endogenous yeast polypeptide comprising a portion of the amino terminal region of said hybrid polypeptide coded for includes a sequence of amino acid residues



- 20 -

duplicative of one or more sequences extant in the amino terminal region of the polypeptide precursor of yeast mating factor α .

- 5 4. A DNA sequence according to claim 3 wherein an amino acid sequence duplicated is as follows:

NH₂-Met-Arg-Phe-Pro-Ser-Ile-Phe-Thr-Ala-Val-Leu-Phe-Ala-Ala-Ser-Ser-Ala-Leu-Ala-Ala-Pro-Val-COO-.

- 10 5. A DNA sequence according to claim 3 wherein an amino acid sequence duplicated in said hybrid polypeptide is as follows:

-NH-Asn-Thr-Thr-Thr-Glu-Asp-Glu-Thr-Ala-Gln-Ile-Pro-Ala-Glu-Ala-Val-Ile-Gly-Tyr-Ser-Asp-Leu-Glu-Gly-Asp-Phe-Asp-
15 Val-Ala-Val-Leu-Pro-Phe-Ser-Asn-Ser-Thr-Asn-Asn-Gly-Leu-Leu-Phe-Ile-Asn-Thr-Thr-Ile-Ala-Ser-Ile-Ala-Ala-Lys-Glu-Glu-Gly-Val-Ser-Leu-Asp-COO-.

- 20 6. A DNA sequence according to claim 3 wherein an amino acid sequence duplicated in said hybrid polypeptide is selected from the group consisting of:

-NH-Lys-Arg-Glu-Ala-Glu-Ala-COO-, or
-NH-Lys-Arg-Glu-Ala-Glu-Ala-Glu-Ala-COO-, or
-NH-Lys-Arg-Glu-Ala-Asp-Ala-Glu-Ala-COO-.

- 25 7. A DNA sequence according to claim 3 wherein an amino acid sequence duplicated in said hybrid polypeptide is as follows:

30 NH₂-Met-Arg-Phe-Pro-Ser-Ile-Phe-Thr-Ala-Val-Leu-Phe-Ala-
20 Ala-Ser-Ser-Ala-Leu-Ala-Ala-Pro-Val-Asn-Thr-Thr-Thr-Glu-
30 Asp-Glu-Thr-Ala-Gln-Ile-Pro-Ala-Glu-Ala-Val-Ile-Gly-Tyr-
40 Ser-Asp-Leu-Glu-Gly-Asp-Phe-Asp-Val-Ala-Val-Leu-Pro-Phe-
50
35 Ser-Asn-Ser-Thr-Asn-Asn-Gly-Leu-Leu-Phe-Ile-Asn-Thr-Thr-
60



- 21 -

70
Ile-Ala-Ser-Ile-Ala-Ala-Lys-Glu-Gly-Val-Ser-Leu-Asp-
80
Lys-Arg-Glu-Ala-Glu-Ala-COO-.

- 5 8. A DNA sequence according to claim 1 wherein
a portion of the carboxyl terminal region of said hybrid
polypeptide coded for also comprises an endogenous poly-
peptide including a sequence of amino acid residues
duplicative of one or more sequences (1) extant in the
10 carboxyl terminal region of an endogenous polypeptide
precursor of a yeast-secreted polypeptide, and (2)
normally proteolytically cleaved from the yeast-secreted
portion of the precursor polypeptide prior to secretion.
- 15 9. A DNA sequence according to claim 8 wherein
the endogenous yeast polypeptide comprising a portion
of the carboxyl terminal region of said hybrid polypep-
tide coded for includes a sequence of amino acid residues
duplicative of one or more sequences extant in the carb-
20 oxyl terminal region of a polypeptide precursor of yeast
mating factor α .
10. A DNA sequence according to claim 9
wherein an amino acid sequence duplicated in said hybrid
25 polypeptide is selected from the group consisting of:
-NH-Lys-Arg-Glu-Ala-Glu-Ala-Glu-Ala-COO-; and
-NH-Lys-Arg-Glu-Ala-Asp-Ala-Glu-Ala-COO-.
11. A DNA sequence according to claim 1
30 wherein the exogenous polypeptide in the carboxyl term-
inal region of the hybrid polypeptide coded for is a
mammalian polypeptide.
12. A DNA sequence according to claim 11
35 wherein the mammalian polypeptide is human β -endorphin.



- 22 -

13. A yeast cell transformation vector comprising a DNA sequence according to claim 1.
14. A yeast cell transformation vector according to claim 13 wherein expression of said DNA sequence is regulated by a promoter/regulator DNA sequence duplicative of that regulating endogenous expression of the selected precursor polypeptide.
15. A yeast cell transformation vector according to claim 13 which is plasmid pYcE, ATCC No. 40068.
16. A yeast cell transformation vector according to claim 13 which is plasmid pYcE, ATCC No. 40069.
17. A method for production of a selected exogenous polypeptide in yeast cells comprising:
transforming yeast cells with a DNA vector according to claim 13;
incubating yeast cells so transformed under conditions facilitative of yeast cell growth and multiplication, the transcription and translation of the DNA sequence comprising said vector, and the intracellular processing toward secretion of said selected exogenous polypeptide into the yeast cell periplasmic space and/or the yeast cell growth medium; and
isolating the selected exogenous polypeptide from the yeast cell periplasmic space and/or the yeast cell growth medium.
18. A method for securing production in yeast cells of polypeptide products displaying one or more of the biological activities of human β -endorphin comprising:
transforming yeast cells with a DNA vector according to claim 15 or claim 16;



- 23 -

incubating yeast cells so transformed under conditions facilitative of yeast cell growth and multiplication, transcription and translation of said DNA sequence coding for a hybrid, [Leu⁵] β -endorphin-
5 containing, polypeptide in said vector, and the intracellular processing toward secretion of polypeptide products displaying one or more of the biological activities of β -endorphin into the yeast cell growth medium;
10 and
isolating the desired polypeptide products from the yeast cell growth medium.

15

20

25

30

35

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US84/00601

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)

According to International Patent Classification (IPC) or to both National Classification and IPC

U.S. 7 435/70
IPC: G012P 21/02

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System

Classification Symbols

U.S. 435/68, 60, 172.3, 172(foreign), 255, 317;
536/27Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched *Biosis Previews 1969-1984
Chemical Abstracts 1967-1984Protein Identification
ResourceIII. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴

Category *	Citation of Document, with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
X	N, Miyachara et al., Proc. Natl. Acad. Sci., USA, Vol. 80, No. 1, issued January 1983, Pages 1-5.	1,2,8,13-17
Y	N, Kurjan et al., Cell, Vol. 30, No. 3, issued October 1982, Pages 933-943.	1-10,13-17
Y	US, A, 4,350,764, published 21 September 1982, Baxter et al.	11,12,18
A	EP, A, 0060057, published 15 September 1982 Hitzeman et al.	1,8,11,13-17
A,P	N, Stepien, et al., Gene, Vol. 24, No. 2-3, issued December 1983, Pages 289-297.	1,8,11,13-17
A	EP, A, 0073635, published 9 March 1983, Kingsman et al.	1,8,11,13-17
A,P	US, A, 4,430,428, published 7 February 1984, Fraser et al.	1,8,11,13-17
A,P	US, A, 4,443,539, published 17 April 1984, Fraser et al.	1,8,11,13-17

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another claim or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search *

21 June 1984

Date of Mailing of this International Search Report *

03 JUL 1984

International Searching Authority *

ISA/US

Signature of Authorized Officer ¹⁹

J. Peter Fasse